Getting the dose escalation schedule right is the single most important factor determining whether you complete semaglutide therapy successfully or quit due to unbearable side effects. The FDA-approved titration schedule was designed for clinical trial compliance rates — in practice, many clinicians modify it to improve tolerability. Rushing to maximum dose is the #1 mistake patients and inexperienced providers make.
Telehealth FX clinicians customize your titration based on your individual tolerance, metabolic response, and weight loss trajectory. This guide covers the standard schedule, when to hold or extend a tier, the microdosing approach for sensitive patients, and the maintenance dosing strategy once you reach your goal.
The Standard Semaglutide Titration Schedule
| Weeks | Dose | Purpose | Expected Side Effects |
|---|---|---|---|
| 1–4 | 0.25mg | GI acclimation only | Mild nausea (30–40%); minimal weight loss |
| 5–8 | 0.5mg | Begin therapeutic effect | Moderate nausea; appetite suppression begins; 2–5 lbs lost |
| 9–12 | 1.0mg | First therapeutic dose | Strong appetite suppression; food noise silenced; 5–10 lbs lost |
| 13–16 | 1.7mg | Enhanced weight loss | GI effects may briefly return; 10–20 lbs lost |
| 17+ | 2.4mg (max) | Maximum therapeutic dose | Usually well-tolerated; 1–2 lbs/week sustained loss |
When to Hold or Extend a Dose Tier
The biggest mistake is escalating through nausea. If you are experiencing significant GI side effects at any dose level, stay at that dose for an additional 2–4 weeks before escalating. Signs you should hold:
- Vomiting more than once per week
- Unable to eat at least 1,000 calories daily
- Losing weight too rapidly (>3 lbs/week sustained, risking loose skin and gallstones)
- Experiencing severe constipation that does not respond to fiber and hydration
Conversely, you may not need to reach 2.4mg. Many patients achieve excellent results at 1.0 or 1.7mg. If you are losing 1–2 lbs/week at a lower dose with manageable side effects, there is no clinical reason to escalate further. See our nausea management guide for strategies at each tier.
Get Expert Titration Guidance
Our clinicians customize your escalation schedule to maximize results and minimize side effects. From $199/mo. HSA/FSA accepted.
Start Your EvaluationMaintenance Dosing: What Happens at Goal Weight?
Reaching your target weight does not mean stopping the medication — discontinuation leads to weight regain in 60–70% of patients within 12 months. Instead, most clinicians recommend stepping down to a lower maintenance dose — typically 0.5mg or 1.0mg semaglutide — that preserves appetite control and metabolic benefits at lower cost and fewer side effects.
Tirzepatide Dose Escalation Comparison
For reference, tirzepatide follows a similar but distinct schedule: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg, with 4-week intervals. Tirzepatide is generally better tolerated at equivalent efficacy tiers. If you are deciding between the two, see our side effects comparison.
Frequently Asked Questions
Can I skip the lower doses and start at 1.0mg?
This is strongly discouraged. Starting above 0.25mg dramatically increases nausea, vomiting, and early discontinuation. The low starting doses allow your GI tract to acclimate to delayed gastric emptying. Patience at the beginning pays dividends in long-term adherence.
What if I miss a dose?
If less than 48 hours late, take the injection as soon as possible. If more than 48 hours late, skip the dose and resume your regular schedule on the next injection day. Do not double dose. If you miss 2+ consecutive doses, consider dropping back one tier and re-titrating.
What time of day should I inject?
Semaglutide can be injected at any time. Most clinicians recommend morning injection after eating to minimize nausea. See best injection timing guide. Consistency is more important than specific timing.
Personalized Titration. From $199/mo.
Custom dosing, not one-size-fits-all. FDA-registered pharmacies. Independently verified.
Start Your EvaluationReferences
- FDA Prescribing Information — Wegovy (semaglutide injection) 2.4mg. Dosage and Administration.
- Wilding, J. P. H., et al. (2021). STEP 1 dose-response analysis. NEJM, 384(11), supplementary appendix.
- Rubino, D., et al. (2022). STEP 4 — Continued treatment vs withdrawal. JAMA, 327(14), 1414–1425.
- Novo Nordisk. (2024). Semaglutide Clinical Pharmacology Review. FDA submission documents.
